Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928472 · ClinicalTrials.gov registry record · Phase 1
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
A Phase 1 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 1
- Development phase
- 402
- Enrollment target
NCT01928472 is a Phase 1 study that has completed, run by Novartis Vaccines. The registered enrollment target is 402 participants.
The verdict
NCT01928472, a Phase 1 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 402 participants
- Enrollment target
Study Summary
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
Interventions
- BIOLOGICAL H7N9c low dose with adjuvant
- BIOLOGICAL H7N9c medium dose with adjuvant
- BIOLOGICAL H7N9c high dose with adjuvant
- BIOLOGICAL H7N9c high dose without adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928472
The ClinicalTrials.gov registry entry for NCT01928472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which H7N9c low dose with adjuvant is the first listed.
NCT01928472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928472 about?
NCT01928472 is a clinical study titled "Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years". Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
What is the current status of trial NCT01928472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 402 participants. The study started on 2013-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01928472?
The interventions under investigation include: H7N9c low dose with adjuvant (BIOLOGICAL), H7N9c medium dose with adjuvant (BIOLOGICAL), H7N9c high dose with adjuvant (BIOLOGICAL), H7N9c high dose without adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01928472?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.